Fig. 2: Efficacy of HER3-DXd.
From: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
a, Waterfall plot showing the best percentage change in the sum of tumor diameters from BL. The bars colored green, blue, purple and red represent CR, PR, SD and PD, respectively. The response was determined by investigator assessment according to RECIST v.1.1 and required confirmation after the first observed response at least 4 weeks later. The Clopper–Pearson (exact) method was used for the CIs. b, Kaplan–Meier estimates of PFS as assessed by a local investigator (median 9.2 months (95% CI [8.0–12.8 months]). c, Kaplan–Meier estimates of duration of response as assessed by a local investigator (median 9.3 months (95% CI 8.2 months–N/A)). aPatients who developed new lesions; bClopper–Pearson (exact) method used for the 90% CI; ctwo patients not evaluable (NE) for ORR: one patient had only one tumor assessment with PR and then treatment discontinued due to clinical progression and a second patient had no evaluable global response-of-target lesions.
